Sunflower Pharmaceutical GroupLtd Crecimiento futuro
Future controles de criterios 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Sunflower Pharmaceutical GroupLtd.
Información clave
n/a
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 19.3% |
| Tasa de crecimiento de los ingresos | n/a |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | None |
| Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
No hay actualizaciones
Recent updates
A Look At The Intrinsic Value Of Sunflower Pharmaceutical Group Co.,Ltd (SZSE:002737)
Aug 26
Lacklustre Performance Is Driving Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Low P/E
Jul 19Sunflower Pharmaceutical GroupLtd's (SZSE:002737) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 07Earnings Troubles May Signal Larger Issues for Sunflower Pharmaceutical GroupLtd (SZSE:002737) Shareholders
May 06Sunflower Pharmaceutical Group Co.,Ltd's (SZSE:002737) Subdued P/E Might Signal An Opportunity
Apr 16We Ran A Stock Scan For Earnings Growth And Sunflower Pharmaceutical GroupLtd (SZSE:002737) Passed With Ease
Mar 04En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Sunflower Pharmaceutical GroupLtd no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.
Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.
Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 9/30/2024 | 4,432 | 855 | -15 | 103 | N/A |
| 6/30/2024 | 5,194 | 967 | 254 | 372 | N/A |
| 3/31/2024 | 5,453 | 968 | 718 | 845 | N/A |
| 12/31/2023 | 5,700 | 1,119 | 741 | 890 | N/A |
| 9/30/2023 | 6,100 | 1,209 | 1,436 | 1,582 | N/A |
| 6/30/2023 | 5,879 | 1,104 | 1,711 | 1,859 | N/A |
| 3/31/2023 | 5,662 | 1,054 | 1,670 | 1,794 | N/A |
| 1/1/2023 | 5,095 | 867 | 1,822 | 1,975 | N/A |
| 9/30/2022 | 4,675 | 813 | 1,112 | 1,252 | N/A |
| 6/30/2022 | 4,608 | 799 | 749 | 908 | N/A |
| 3/31/2022 | 4,443 | 698 | 925 | 1,075 | N/A |
| 1/1/2022 | 4,461 | 705 | 747 | 865 | N/A |
| 9/30/2021 | 4,271 | 668 | 775 | 914 | N/A |
| 6/30/2021 | 3,964 | 655 | 978 | 1,166 | N/A |
| 3/31/2021 | 3,769 | 656 | 930 | 1,143 | N/A |
| 12/31/2020 | 3,462 | 584 | 957 | 1,170 | N/A |
| 9/30/2020 | 3,427 | 509 | 886 | 1,184 | N/A |
| 6/30/2020 | 3,585 | 497 | 699 | 1,012 | N/A |
| 3/31/2020 | 4,069 | 557 | 698 | 1,052 | N/A |
| 12/31/2019 | 4,371 | 565 | 607 | 981 | N/A |
| 9/30/2019 | 4,488 | 591 | 684 | 1,028 | N/A |
| 6/30/2019 | 4,523 | 586 | 700 | 1,013 | N/A |
| 3/31/2019 | 4,594 | 580 | 538 | 882 | N/A |
| 12/31/2018 | 4,472 | 563 | 545 | 866 | N/A |
| 9/30/2018 | 4,369 | 524 | 578 | 820 | N/A |
| 6/30/2018 | 4,234 | 515 | N/A | 639 | N/A |
| 3/31/2018 | 4,111 | 472 | N/A | 689 | N/A |
| 12/31/2017 | 3,855 | 424 | N/A | 567 | N/A |
| 9/30/2017 | 3,855 | 426 | N/A | 490 | N/A |
| 6/30/2017 | 3,785 | 328 | N/A | 524 | N/A |
| 3/31/2017 | 3,435 | 305 | N/A | 230 | N/A |
| 12/31/2016 | 3,364 | 303 | N/A | 341 | N/A |
| 9/30/2016 | 3,045 | 230 | N/A | -71 | N/A |
| 6/30/2016 | 3,057 | 291 | N/A | -111 | N/A |
| 3/31/2016 | 3,094 | 319 | N/A | 93 | N/A |
| 12/31/2015 | 3,035 | 307 | N/A | 126 | N/A |
| 9/30/2015 | 2,981 | 307 | N/A | 211 | N/A |
| 6/30/2015 | 2,980 | 319 | N/A | 382 | N/A |
| 3/31/2015 | 2,820 | 312 | N/A | 421 | N/A |
| 12/31/2014 | 2,719 | 301 | N/A | 403 | N/A |
| 9/30/2014 | 2,567 | 268 | N/A | 425 | N/A |
| 12/31/2013 | 2,181 | 263 | N/A | 293 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Insufficient data to determine if 002737's forecast earnings growth is above the savings rate (2.9%).
Beneficios vs. Mercado: Insufficient data to determine if 002737's earnings are forecast to grow faster than the CN market
Beneficios de alto crecimiento: Insufficient data to determine if 002737's earnings are expected to grow significantly over the next 3 years.
Ingresos vs. Mercado: Insufficient data to determine if 002737's revenue is forecast to grow faster than the CN market.
Ingresos de alto crecimiento: Insufficient data to determine if 002737's revenue is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if 002737's Return on Equity is forecast to be high in 3 years time